CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024and Provides Business Update   Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first d [ … ]

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025  TÜBINGEN, Germany/BOSTON, USA – April 08, 2025 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial result [ … ]

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac’s investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC e [ … ]

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025 [ … ]

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators   CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA techno [ … ]